SMC Update - February 2022
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Cannabidiol (Epidyolex®) has been accepted for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older. This advice applies only in the context of an approved NHSScotland Patient Access Scheme and it is therefore expected that this medication will be supplied direct from the specialist. There is existing NICE and SMC advice on the use of this medicine for seizures associated with Dravet syndrome and Lennox–Gastaut syndrome.
Cenobamate (Ontozry®) has been accepted for restricted use as an adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products. The restriction limits use to patients with drug-resistant epilepsy as a second-line adjunctive anti-seizure medicine, after the failure of the first adjunctive anti-seizure medicine.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « CKS Updates - January 2022 | Drug Safety Update - February 2022 » |
Leave a Comment